Key result
Treprostinil induces endothelial-dependent relaxation in pulmonary artery microgauges, enabling high-throughput screening.
Why the study?
Systems recapitulating endothelial-dependent regulation of smooth muscle cell contractility were needed to model pulmonary arterial vasoregulation.
This novel microtissue platform enables high-throughput quantification of endothelial-dependent vasorelaxation, facilitating mechanistic studies and drug screening for pulmonary arterial hypertension.
systems that recapitulate endothelial-dependent regulation of smooth muscle cell contractility. Here, we microfabricated pulmonary artery smooth muscle microgauges (PA-SMUGs) that enable quantification of contractile forces generated by human pulmonary arterial smooth muscle cells (PASMCs) within microtissues that contain a functional monolayer of pulmonary arterial endothelial cells (PAECs). PA-SMUGs demonstrate PAEC-dependent vasorelaxation and respond to treprostinil, a clinically approved PAH therapy. This platform, which establishes a high-throughput method for quantifying EC-dependent vasorelaxation, will facilitate mechanistic studies into the role of PAEC-PASMC crosstalk in PAH pathogenesis and enable screening for novel therapeutics to improve PAH outcomes and hypertensive diseases more broadly.
No takes yet. Share an insight, caveat, or question.
Sawhney et al. (2025) studied Pulmonary arterial hypertension. Pulmonary artery smooth muscle microgauges (PA-SMUGs) was evaluated on Quantification of contractile forces and EC-dependent vasorelaxation. Microfabricated pulmonary artery smooth muscle microgauges (PA-SMUGs) demonstrated endothelial cell-dependent vasorelaxation and responded to treprostinil, establishing a high-throughput screening method.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: